Expression of the glioma-associated oncogene homolog 1 (gli1) in advanced serous ovarian cancer is associated with unfavorable overall survival

• Published in: PloS one Vol. 8; no. 3; p. e60145
• Main Authors: Ciucci, Alessandra, De Stefano, Ilaria, Vellone, Valerio Gaetano, Lisi, Lucia, Bottoni, Carolina, Scambia, Giovanni, Zannoni, Gian Franco, Gallo, Daniela
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 28.03.2013; Public Library of Science (PLoS)
• Subjects: Adult; Aged; Biology; Biotechnology; Blotting, Western; Brain tumors; Cancer; Cell growth; Cell Line, Tumor; Cell proliferation; Cell Proliferation - drug effects; Chemotherapy; Cinnamates - pharmacology; Colorectal carcinoma; Epithelial cells; Female; Gene expression; Glioblastoma; Glioma; Gynecology; Hedgehog protein; Histopathology; Homology; Humans; Immunoprecipitation; Ligands; Medical prognosis; Medicine; Medulloblastoma; Melanoma; Middle Aged; Multivariate analysis; Mutation; Obstetrics; Oncogenes; Ovarian cancer; Ovarian carcinoma; Ovarian Neoplasms - genetics; Ovarian Neoplasms - metabolism; Ovarian Neoplasms - pathology; Ovaries; Pancreas; Pancreatic carcinoma; Pathogenesis; Prostate; Prostate cancer; Prostate carcinoma; Proteins; Real-Time Polymerase Chain Reaction; Signaling; Survival; Therapeutic applications; Transcription Factors - genetics; Transcription Factors - metabolism; Tumor cell lines; Tumors; Veratrum Alkaloids - pharmacology; Zinc Finger Protein GLI1; Italy
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0060145

Recent evidence links aberrant activation of Hedgehog (Hh) signaling with the pathogenesis of several cancers including medulloblastoma, glioblastoma, melanoma as well as pancreas, colorectal, and prostate carcinomas. Here we investigated the role of the transcription factor Gli1 in ovarian cancer. To this end, the expression profile of Gli1 was examined in normal ovaries, ovarian tumors, and ovarian cancer cell lines, and the in vitro effects of a specific Hh-pathway blocker, KAAD-cyclopamine, or a specific Gli1 inhibitor (GANT58) on cell proliferation and on Hh target gene expression were also assessed. Results obtained showed that epithelial cells in ovarian cancer tissue express significantly higher levels of nuclear Gli1 than in normal ovarian tissue, where the protein was almost undetectable. In addition, multivariate analysis showed that nuclear Gli1 was independently associated to poor survival in advanced serous ovarian cancer patients (HR = 2.2, 95%CI 1.0-5.1, p = 0.04). In vitro experiments demonstrated Gli1 expression in the three ovarian carcinoma cell lines tested, A2780, SKOV-3 and OVCAR-3. Remarkably, although KAAD-cyclopamine led to decreased cell proliferation, this treatment did not inhibit hedgehog target gene expression in any of the three ovarian cancer cell lines, suggesting that the inhibition of cell proliferation was a nonspecific or toxic effect. In line with these data, no differences on cell proliferation were observed when cell lines were treated with GANT58. Overall, our clinical data support the role of Gli1 as a prognostic marker in advanced serous ovarian cancer and as a possible therapeutic target in this disease. However, our in vitro findings draw attention to the need for selection of appropriate experimental models that accurately represent human tumor for testing future therapies involving Hh pathway inhibitors.